When it comes to sexual health, a diagnosis isn’t always crystal clear. In fact, co-infections can play a significant role in vaginitis symptoms, complicating diagnosis and treatment. Identifying and addressing co-infections is crucial for effective care and symptom relief. Cepheid’s Xpert® Xpress MVP simplifies testing for common causes of vaginitis and co-infections, all in one comprehensive test. Let’s empower patients with clarity and confidence. Learn more about Xpert Xpress MVP. #STIAwarness #WomensHealth US-IVD. In Vitro Diagnostic Medical Device. Learn More: https://ow.ly/FFof50VuQqj
About us
Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings. For more information, visit http://www.cepheid.com. Cepheid is proud to be a part of Danaher. Danaher’s science and technology leadership puts Cepheid’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics, and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.
- Website
-
http://www.cepheid.com
External link for Cepheid
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Sunnyvale, CA
- Type
- Public Company
- Founded
- 1996
- Specialties
- Molecular Diagnostics, Genetic Testing, Molecular Biology, Infectious Diseases, Cancer, and PCR
Locations
-
Primary
904 Caribbean Drive
Sunnyvale, CA 94089, US
-
Vira Solelh
Maurens-Scopont, 81470, FR
-
Aston Court
Kingsmead Business Park, Frederick Place
High Wycombe, Buckinghamshire HP11 1LA, GB
-
Röntgenv 2
Solna, 171 54, SE
Employees at Cepheid
Updates
-
For the first time, Cepheid and Beckman Coulter Diagnostics are attending ESCMID Global together! Find us at the Danaher booth #E10, where we are united behind the shared goal of solving complex health challenges for patients around the world, enabling healthcare providers to diagnose diseases with unprecedented speed and precision. Check out our in-booth presentation schedule and get the sessions on your calendar: https://ow.ly/A77S50VfV9G #ESCMID #InfectiousDisease
-
ECDC CPE Update Alert! The latest ECDC update calls for action against antimicrobial resistance: ✅ Develop a CRE management plan ✅ Implement enhanced IPC measures ✅ Apply antimicrobial stewardship ✅ Strengthen genomic surveillance ✅ Provide adequate lab capacity Due to high spread risk, ECDC urges surveillance of asymptomatic CPE carriers in the EU. Differentiating carbapenemase families is necessary for surveillance and treatment.(1) Xpert® Carba-R aligns with ECDC recommendations, offering rapid detection and differentiation of NDM, VIM, IMP, KPC, OXA-48 in just 50 minutes. #AMR #ECDC #CPE Stay informed and let’s take action together. Click here to download this update now: https://ow.ly/QmMN50VtmYa (1) European Centre for Disease Prevention and Control. Carbapenem-resistant Enterobacterales, third update – 3 February 2025. ECDC: Stockholm; 2025.
-
-
💡 Cristina Baker, Cepheid’s Senior Director of Medical and Scientific Affairs, discusses how scientific innovation can help bring us closer to an end to tuberculosis #EndTB 📲 Read her Expert Perspective on Cepheid’s Insight Hub: https://lnkd.in/gkjDfgTN
-
⚔ Fighting TB is everything: How South Africa has landed a significant blow on its tuberculosis burden. 🌏 Few things in global health are as worth investing in as childhood vaccination programs. Data from a new study suggest molecular diagnostics for tuberculosis (TB) might be one of them. 🔎 Read the impact evidence on Cepheid’s Insight Hub: https://ow.ly/Lwm450VqQ0H #EndTB BMJ
-
For nearly three decades, we’ve strived to improve healthcare by developing diagnostic solutions that are fast, accurate, and flexible. #MolecularDiagnostics #BestTeamWins Learn more about our mission here: https://ow.ly/Tc0950VcZM4
-
-
Cepheid celebrates National Doctor’s Day and honors the dedication and compassion displayed daily by more than one million physicians providing healthcare to patients nationwide. #NationalDoctorsDay #BestTeamWins
-
-
🌏 Tuberculosis is an urgent public health concern, especially globally, resurging as the world’s deadliest infectious disease. An often-overlooked piece of the story, however, is the impact of TB in the U.S. 🏥 While its prevalence is lower than in other parts of the world, it is still dangerous to communities and costly to hospital systems at home. So, what can we learn from our testing abroad? ... 📗 Read the complete Expert Perspective by our Vice President of Scientific Affairs, Mike Loeffelholz, on Cepheid’s Insight Hub: https://lnkd.in/gd_CYhFH #EndTB
-
📊 Let's follow the numbers to #EndTB. 📑 A study published in BMJ examines the health impact, economic impact, and return on investment of the South African molecular diagnostics program for HIV, tuberculosis, and SARS-CoV-2. 💡 Congratulations to the authors on this insightful publication. Access the “10-years of impact” infographic on Cepheid’s Insight Hub: https://lnkd.in/gcCk2J6p
-
The Desmond Tutu Health Foundation has spent the past 20 years trying to reduce the impact of HIV, TB, and other communicable diseases in some of the hardest-hit communities in South Africa. #TB #EndTB Watch to learn how they are going it: https://ow.ly/jSl650VmskS
Affiliated pages
Similar pages
Browse jobs
Stock
DHR
NYSE
20 minutes delay
$181.77
-16.13 (-8.151%)
- Open
- 195.46
- Low
- 181.2
- High
- 195.46
Data from Refinitiv
See more info on